English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/155101
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia

AuthorsRuiz-Llorente, Lidia ; Gallardo-Vara, Eunate ; Rossi, Elisa; Smadja, David M.; Botella, Luisa María ; Bernabéu, Carmelo
KeywordsHHT
Endoglin
ALK1
Haploinsufficiency
Bleeding
Angiogenesis
AVM
Bevacizumab
Thalidomide
Issue DateOct-2017
PublisherTaylor & Francis
CitationExpert Opin Ther Targets. 21(10):933-947 (2017)
AbstractIntroduction: Hereditary Haemorrhagic Telangiectasia (HHT) is as an autosomal dominant trait characterized by frequent nose bleeds, mucocutaneous telangiectases, arteriovenous malformations (AVMs) of the lung, liver and brain, and gastrointestinal bleedings due to telangiectases. HHT is originated by mutations in genes whose encoded proteins are involved in the transforming growth factor β (TGF-β) family signalling of vascular endothelial cells. In spite of the great advances in the diagnosis as well as in the molecular, cellular and animal models of HHT, the current treatments remain just at the palliative level.
Areas covered: Pathogenic mutations in genes coding for the TGF-β receptors endoglin (ENG) (HHT1) or the activin receptor-like kinase-1 (ACVRL1 or ALK1) (HHT2), are responsible for more than 80% of patients with HHT. Therefore, ENG and ALK1 are the main potential therapeutic targets for HHT and the focus of this review. The current status of the preclinical and clinical studies, including the antiangiogenic strategy, have been addressed.
Expert opinion: Endoglin and ALK1 are attractive therapeutic targets in HHT. Because haploinsufficiency is the pathogenic mechanism in HHT, several therapeutic approaches able to enhance protein expression and/or function of endoglin and ALK1 are keys to find novel and efficient treatments for the disease.
Publisher version (URL)http://dx.doi.org/10.1080/14728222.2017.1365839
URIhttp://hdl.handle.net/10261/155101
DOI10.1080/14728222.2017.1365839
ISSN1472-8222
E-ISSN1744-7631
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Ruiz-Llorente EOTT 2017 .pdfArtículo principal2,74 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.